Beam Therapeutics Inc. (BEAM, Financial) experienced a notable stock movement, with its price surging by 5.02%. The stock recently traded at $24.08 per share with a volume of 406,889 shares, reflecting a turnover rate of 0.49% and a volatility of 6.78%.
In its recent financial report, Beam Therapeutics posted a revenue of $11.77 million against a net loss of $91.05 million, resulting in an earnings per share of -$1.11. The company's gross profit stood at $6.20 million, with a price-to-earnings ratio of -14.86.
Analyst ratings show a split perspective, with 50% of the 18 participating firms recommending a buy and the remaining 50% suggesting a hold, while no firms rated it a sell.
Within the biotechnology sector, where Beam Therapeutics is positioned, the overall index dropped slightly by 0.01%. Related stocks such as Neurogene Inc., Tenaya Therapeutics, Inc., and Disc Medicine, Inc. saw significant gains. Meanwhile, Elevai Labs, Inc., Nls Pharmaceutics Ltd., and Gri Bio, Inc. showed high trading activity, with turnover rates of 376.36%, 275.29%, and 79.72%, respectively. The most volatile stocks included Sab Biotherapeutics Inc C/Wts 22/10/2026 (To Pur Com), In8Bio, Inc., and Neurogene Inc., with fluctuations of 52.25%, 45.39%, and 39.98% respectively.
Beam Therapeutics is a biotechnology firm that focuses on developing gene therapies using its base editing technology. This innovative approach targets individual bases in the genome without causing double-strand DNA breaks. The company's projects include gene correction, modification, activation, silencing, and multiplex editing, with pipeline initiatives such as BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
